In a recent study published in JAMA Network Open, researchers from Singapore found that adults hospitalized for respiratory syncytial virus (RSV) faced a greater risk of heart problems than those admitted for the flu or COVID-19 (specifically the Omicron variant).
The study analyzed data from nearly 33,000 adults who were hospitalized due to RSV, flu, or COVID-19 between January 2017 and June 2024. It revealed that 10.9% of RSV patients experienced serious heart issues, including abnormal heart rhythms, heart failure, and ischemic heart disease. Most of these incidents were related to irregular heartbeats, with atrial fibrillation being the most common type.
Among patients with a history of heart disease, the likelihood of experiencing a heart problem during RSV hospitalization was more than double compared to those infected with the flu or COVID-19. The study also indicated that patients with COVID-19 who received three vaccine doses had a lower risk for heart issues compared to those with RSV.
The researchers noted that the strain on the heart may come from direct injury or from the body’s inflammatory response to the viral infection. They stressed the importance of vaccinations for older adults and individuals with preexisting heart conditions, especially since there are now vaccines available for RSV.
Overall, this study highlights the significant cardiac risks associated with RSV and underscores the need for prioritizing vaccination in vulnerable populations.
